<DOC>
	<DOC>NCT01225809</DOC>
	<brief_summary>Patients who were vaccinated with AFFITOPE AD01 during AFFiRiS001 will undergo a long-term follow-up period to get more information regarding the safety profile of AFFITOPE AD01.</brief_summary>
	<brief_title>AD01 Follow up Extension Visit</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Written informed consent signed and dated by the patient or the patient's legal representative and the caregiver. Patients having participated in AFFiRiS 001 and AFF003 and having received â‰¥1 vaccination with AFFITOPE AD01 Availability of a partner/caregiver knowing the patient Patients having received no vaccination with AFFITOPE AD01 History of questionable compliance to visit schedule</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>AD01 follow-up extension</keyword>
</DOC>